Minerva Neurosciences (NASDAQ:NERV) Research Coverage Started at StockNews.com

Posted by Joseph Casey on Feb 25th, 2025

StockNews.com initiated coverage on shares of Minerva Neurosciences (NASDAQ:NERV – Free Report) in a research note released on Saturday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reissued a “neutral” rating and issued a $5.00 price target on shares of Minerva Neurosciences in a research report on Wednesday, November 6th.

Get Our Latest Stock Analysis on Minerva Neurosciences

Minerva Neurosciences Stock Down 1.6 %

NASDAQ:NERV opened at $1.79 on Friday. Minerva Neurosciences has a 12-month low of $1.77 and a 12-month high of $7.53. The firm has a market capitalization of $12.52 million, a PE ratio of -4.07 and a beta of 0.12. The firm has a 50-day moving average price of $2.18 and a 200 day moving average price of $2.41.

Institutional Trading of Minerva Neurosciences

An institutional investor recently raised its position in Minerva Neurosciences stock. Citadel Advisors LLC grew its position in shares of Minerva Neurosciences, Inc. (NASDAQ:NERV – Free Report) by 49.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 25,764 shares of the biopharmaceutical company’s stock after buying an additional 8,525 shares during the quarter. Citadel Advisors LLC owned approximately 0.37% of Minerva Neurosciences worth $57,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 34.56% of the company’s stock.

Minerva Neurosciences Company Profile

(Get Free Report)

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.